Brief Title
Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
Official Title
A Prospective, Non-interventional, Observational, Multi-centre Study to Document QoL of Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
Brief Summary
The purpose of the protocol is to evaluate and describe QoL, in the population of Polish acromegalic patients treated with Lanreotide Autogel® 120 mg during the 24 months (long term observation).
Study Type
Observational
Primary Outcome
Acromegaly quality of life (AcroQol) questionnaire
Secondary Outcome
Hormonal control of serum growth hormone (GH) and insulin-like growth factor 1 (IGF-1) concentration
Condition
Acromegaly
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
152
Start Date
December 2014
Completion Date
May 2018
Primary Completion Date
May 2018
Eligibility Criteria
Inclusion Criteria: - Adult patients with acromegaly treated for at least three months and no longer than three years with Lanreotide Autogel® 120 mg just before inclusion. - Patients capable of giving their informed consent to participate in the study and who agree to participate by signing the informed consent form. Exclusion Criteria: - Active participation in any interventional or any other non-interventional acromegaly clinical study. (Previous participation in any interventional or any observational / post marketing study (PMS) of other somatostatin analogue should not be an exclusion criteria). - Any medical or psychological condition, according to investigator judgement, that might compromise the ability to give informed consent.
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Ipsen Medical Director, ,
Location Countries
Poland
Location Countries
Poland
Administrative Informations
NCT ID
NCT02396966
Organization ID
A-38-52030-306
Responsible Party
Sponsor
Study Sponsor
Ipsen
Study Sponsor
Ipsen Medical Director, Study Director, Ipsen
Verification Date
December 2018